Oruka Therapeutics Inc Financials
This page shows Oruka Therapeutics Inc (ORKA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Equity-funded R&D expansion is driving a much larger operating cash burn while the balance sheet stays lightly levered.
FY2025’s operating cash burn of-$88.2M sat close to its net loss of-$105.4M , so the accounting loss is showing up as real cash consumption rather than a temporary working-capital swing. Because capex was only$209K , Oruka is using cash to run research rather than to build a capital-heavy asset base, and the higher share count indicates that burn is being replenished mainly with shareholder capital.
In FY2025, R&D spending reached
Year-end cash slipped to
Financial Health Signals
Oruka Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Oruka Therapeutics Inc passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Oruka Therapeutics Inc reported a net loss of $105.4M while operations used $88.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Oruka Therapeutics Inc's EBITDA was -$122.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 38.4% from the prior year.
Oruka Therapeutics Inc reported -$105.4M in net income in fiscal year 2025. This represents a decrease of 25.9% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Oruka Therapeutics Inc recorded an outflow of $88.4M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 52.4% from the prior year.
Oruka Therapeutics Inc held $46.9M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Oruka Therapeutics Inc's ROE was -22.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 0.4 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Oruka Therapeutics Inc invested $100.6M in research and development in fiscal year 2025. This represents an increase of 34.1% from the prior year.
Oruka Therapeutics Inc invested $209K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 10.6% from the prior year.
Not reported for fiscal year 2025.
ORKA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | N/A | N/A | N/A |
| R&D Expenses | N/A | $100.6M+34.1% | $75.1M+7309.7% | $1.0M-78.7% | $4.7M-65.7% | $13.8M+177.1% | $5.0M+172.3% | $1.8M-56.8% | $4.2M-69.9% | $14.1M+14.0% | $12.3M+74.8% | $7.1M+25.6% | $5.6M+92.1% | $2.9M+168.1% | $1.1M-52.8% | $2.3M |
| SG&A Expenses | N/A | $21.4M+63.9% | $13.1M+107.9% | $6.3M+7.5% | $5.8M+6.3% | $5.5M+15.3% | $4.8M+19.9% | $4.0M+2.6% | $3.9M-16.3% | $4.6M+8.7% | $4.3M-2.9% | $4.4M+8.0% | $4.1M+1.4% | $4.0M+24.3% | $3.2M-36.0% | $5.0M |
| Operating Income | N/A | -$122.1M-38.5% | -$88.1M-1107.8% | -$7.3M+31.1% | -$10.6M+45.2% | -$19.3M-98.0% | -$9.8M-68.0% | -$5.8M+28.4% | -$8.1M+56.6% | -$18.7M-12.6% | -$16.6M-45.0% | -$11.5M-18.2% | -$9.7M-39.7% | -$6.9M-60.7% | -$4.3M+41.3% | -$7.4M |
| Interest Expense | N/A | N/A | $1.5M | N/A | N/A | N/A | $9K+28.6% | $7K-12.5% | $8K+33.3% | $6K | N/A | $4K+33.3% | $3K-25.0% | $4K+33.3% | $3K-40.0% | $5K |
| Income Tax | N/A | N/A | N/A | $0 | $0 | $0+100.0% | -$9K+94.6% | -$167K-438.7% | -$31K+49.2% | -$61K | $0 | $0 | $0 | $0 | N/A | N/A |
| Net Income | N/A | -$105.4M-25.9% | -$83.7M-1468.2% | -$5.3M+46.2% | -$9.9M+48.6% | -$19.3M-98.4% | -$9.7M-77.6% | -$5.5M+30.9% | -$7.9M+57.1% | -$18.5M-12.4% | -$16.4M-43.7% | -$11.4M-18.1% | -$9.7M-39.6% | -$6.9M-60.6% | -$4.3M+19.5% | -$5.4M |
| EPS (Diluted) | — | N/A | -$3.87 | -$0.37+46.4% | -$0.69+50.4% | -$1.39 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ORKA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $488.6M+23.4% | $396.0M+946.0% | $37.9M-12.1% | $43.1M-21.6% | $54.9M+8.9% | $50.4M+490.8% | $8.5M+25.1% | $6.8M-44.8% | $12.4M-49.8% | $24.6M-37.8% | $39.6M+145.3% | $16.1M-5.6% | $17.1M+431.9% | $3.2M-50.6% | $6.5M |
| Current Assets | $343.9M-8.8% | $376.9M+902.5% | $37.6M-12.0% | $42.7M-21.5% | $54.4M+8.9% | $50.0M+489.2% | $8.5M+25.1% | $6.8M-44.9% | $12.3M-42.6% | $21.4M-44.9% | $38.9M+151.3% | $15.5M-8.5% | $16.9M+455.8% | $3.0M-51.0% | $6.2M |
| Cash & Equivalents | $46.9M-23.8% | $61.6M+64.5% | $37.4M-11.8% | $42.4M-20.5% | $53.4M+8.7% | $49.1M+486.8% | $8.4M+26.6% | $6.6M-24.1% | $8.7M+17.6% | $7.4M-80.9% | $38.8M+152.7% | $15.4M-8.4% | $16.8M+473.8% | $2.9M-50.9% | $5.9M |
| Total Liabilities | $16.7M+20.9% | $13.8M+1540.7% | $841K-40.4% | $1.4M-63.6% | $3.9M-0.7% | $3.9M+322.0% | $926K+16.8% | $793K-62.1% | $2.1M-14.2% | $2.4M+61.9% | $1.5M+8.1% | $1.4M-7.5% | $1.5M+392.8% | $305K-60.4% | $770K |
| Current Liabilities | $15.4M+17.9% | $13.0M+1947.6% | $637K-43.7% | $1.1M-67.6% | $3.5M0.0% | $3.5M+277.9% | $926K+16.8% | $793K-61.7% | $2.1M-13.6% | $2.4M+59.3% | $1.5M+8.4% | $1.4M-7.6% | $1.5M+392.5% | $305K-59.5% | $754K |
| Total Equity | $471.9M+23.5% | $382.2M+932.5% | $37.0M-11.2% | $41.7M-18.4% | $51.0M+9.7% | $46.5M+511.3% | $7.6M+26.2% | $6.0M-41.3% | $10.3M-53.7% | $22.2M-41.7% | $38.1M+158.3% | $14.7M-5.4% | $15.6M+436.0% | $2.9M-49.3% | $5.7M |
| Retained Earnings | -$189.2M-125.9% | -$83.7M+55.6% | -$188.7M-2.9% | -$183.4M-5.7% | -$173.5M-12.5% | -$154.2M-6.7% | -$144.4M-3.9% | -$138.9M-6.1% | -$131.0M-16.4% | -$112.5M-17.1% | -$96.1M-13.5% | -$84.6M-12.9% | -$74.9M-10.2% | -$68.0M-6.8% | -$63.7M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
ORKA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$100.9M | -$88.2M-52.5% | -$57.8M-1053.5% | -$5.0M+54.1% | -$10.9M+41.8% | -$18.8M-142.9% | -$7.7M-60.9% | -$4.8M+41.8% | -$8.2M+52.8% | -$17.5M-16.6% | -$15.0M-42.3% | -$10.5M-12.0% | -$9.4M-77.9% | -$5.3M-29.7% | -$4.1M+41.4% | -$7.0M |
| Capital Expenditures | $235K | $209K+10.6% | $189K | $0-100.0% | $2K-95.3% | $43K+126.3% | $19K+375.0% | $4K0.0% | $4K+33.3% | $3K-75.0% | $12K+9.1% | $11K-42.1% | $19K-40.6% | $32K | N/A | $19K |
| Free Cash Flow | -$101.2M | -$88.4M-52.4% | -$58.0M-1057.3% | -$5.0M+54.1% | -$10.9M+42.0% | -$18.8M-142.8% | -$7.7M-61.2% | -$4.8M+41.7% | -$8.2M+52.8% | -$17.5M-16.5% | -$15.0M-42.2% | -$10.5M-11.9% | -$9.4M-77.2% | -$5.3M | N/A | -$7.0M |
| Investing Cash Flow | -$569.9M | -$96.7M+70.7% | -$330.1M | $0+100.0% | -$2K+95.3% | -$43K-126.3% | -$19K-375.0% | -$4K-100.1% | $3.0M-76.4% | $12.9M | N/A | N/A | N/A | -$32K | N/A | $2.0M |
| Financing Cash Flow | $873.8M | $170.3M-62.1% | $449.5M | $0 | $0-100.0% | $23.1M-52.3% | $48.5M+638.6% | $6.6M+111.3% | $3.1M-46.9% | $5.8M | N/A | N/A | N/A | $19.2M+1715.7% | $1.1M-72.7% | $3.9M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ORKA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity | -22.3%-0.4pp | -21.9%-7.5pp | -14.4%+9.4pp | -23.8%+14.0pp | -37.9%-16.9pp | -20.9%+51.1pp | -72.0%+59.5pp | -131.5%+48.4pp | -180.0%-105.9pp | -74.1%-44.0pp | -30.1%+35.7pp | -65.7%-21.2pp | -44.5%+104.1pp | -148.6%-55.0pp | -93.6% |
| Return on Assets | -21.6%-0.4pp | -21.1%-7.0pp | -14.1%+8.9pp | -23.0%+12.1pp | -35.2%-15.9pp | -19.3%+44.9pp | -64.2%+52.0pp | -116.2%+33.3pp | -149.5%-82.8pp | -66.8%-37.8pp | -28.9%+31.1pp | -60.1%-19.4pp | -40.6%+93.9pp | -134.5%-52.0pp | -82.5% |
| Current Ratio | 22.37-6.5x | 28.89-30.1x | 59.01+21.3x | 37.72+22.2x | 15.56+1.3x | 14.28+5.1x | 9.16+0.6x | 8.55+2.6x | 5.94-3.0x | 8.95-16.9x | 25.88+14.7x | 11.16-0.1x | 11.27+1.3x | 9.98+1.7x | 8.24 |
| Debt-to-Equity | 0.040.0x | 0.040.0x | 0.020.0x | 0.030.0x | 0.080.0x | 0.080.0x | 0.120.0x | 0.13-0.1x | 0.20+0.1x | 0.11+0.1x | 0.04-0.1x | 0.090.0x | 0.100.0x | 0.100.0x | 0.13 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Oruka Therapeutics Inc Ranks
Frequently Asked Questions
Is Oruka Therapeutics Inc profitable?
No, Oruka Therapeutics Inc (ORKA) reported a net income of -$105.4M in fiscal year 2025.
What is Oruka Therapeutics Inc's EBITDA?
Oruka Therapeutics Inc (ORKA) had EBITDA of -$122.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Oruka Therapeutics Inc's return on equity (ROE)?
Oruka Therapeutics Inc (ORKA) has a return on equity of -22.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Oruka Therapeutics Inc's free cash flow?
Oruka Therapeutics Inc (ORKA) recorded an outflow of $88.4M in free cash flow during fiscal year 2025. This represents a -52.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Oruka Therapeutics Inc's operating cash flow?
Oruka Therapeutics Inc (ORKA) recorded an outflow of $88.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Oruka Therapeutics Inc's total assets?
Oruka Therapeutics Inc (ORKA) had $488.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Oruka Therapeutics Inc's capital expenditures?
Oruka Therapeutics Inc (ORKA) invested $209K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Oruka Therapeutics Inc spend on research and development?
Oruka Therapeutics Inc (ORKA) invested $100.6M in research and development during fiscal year 2025.
What is Oruka Therapeutics Inc's current ratio?
Oruka Therapeutics Inc (ORKA) had a current ratio of 22.37 as of fiscal year 2025, which is generally considered healthy.
What is Oruka Therapeutics Inc's debt-to-equity ratio?
Oruka Therapeutics Inc (ORKA) had a debt-to-equity ratio of 0.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Oruka Therapeutics Inc's return on assets (ROA)?
Oruka Therapeutics Inc (ORKA) had a return on assets of -21.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Oruka Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Oruka Therapeutics Inc (ORKA) had $46.9M in cash against an annual operating cash burn of $88.2M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Oruka Therapeutics Inc's Piotroski F-Score?
Oruka Therapeutics Inc (ORKA) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Oruka Therapeutics Inc's earnings high quality?
Oruka Therapeutics Inc (ORKA) reported a net loss of $105.4M while operations used $88.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.